PMID- 15069760
OWN - NLM
STAT- MEDLINE
DCOM- 20040421
LR  - 20190917
IS  - 0735-7907 (Print)
IS  - 0735-7907 (Linking)
VI  - 22
IP  - 1
DP  - 2004
TI  - HER-2/neu and p53 in osteosarcoma: an immunohistochemical and fluorescence in 
      situ hybridization analysis.
PG  - 16-24
AB  - The overexpression of HER-2/neu and p53 has been associated with poor outcome in 
      many neoplasms. Their role in patients with osteosarcoma is unclear. We studied 
      the expression of HER-2/neu and p53 in 22 osteosarcoma samples (from 20 
      patients--2 had locally recurrent disease) biopsied at the University of Medicine 
      and Dentistry of New Jersey (UMDNJ) from 1996-2000 using both immunohistochemical 
      (IHC) and fluorescence in situ hybridization (FISH) analysis. Fourteen patients 
      (14 samples) presented with Stage II and 6 patients (8 samples) presented with 
      Stage III disease. Median follow-up is two years (range one year to five years). 
      Four of 22 (18%) samples showed focal membranous or cytoplasmic positivity for 
      HER-2/neu and six of 22 samples (27%) showed nuclear positivity for p53 by IHC 
      analysis. In contrast, none of 22 tested samples showed gene amplification for 
      HER-2/neu by FISH analysis. Seven of 13 HER-2/neu and p53 negative patients (54%) 
      are currently disease free (between one year to five years). In this sample of 
      patients, the HER-2/neu oncogene is not overexpressed or amplified in 
      osteosarcoma; six of 22 samples (27%) showed overexpression of p53 by IHC 
      analysis. By FISH, none of the samples demonstrated deletion of p53. Neither 
      HER2/neu nor p53 expression was important for the biology of osteosarcoma in this 
      population.
FAU - Tsai, James Y
AU  - Tsai JY
AD  - UMDNJ-New Jersey Medical School, Newark, New Jersey, USA. james_tsai@brown.edu
FAU - Aviv, Hana
AU  - Aviv H
FAU - Benevenia, Joseph
AU  - Benevenia J
FAU - Chang, Victor T
AU  - Chang VT
FAU - Patterson, Francis
AU  - Patterson F
FAU - Aisner, Seena
AU  - Aisner S
FAU - Hameed, Meera
AU  - Hameed M
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - England
TA  - Cancer Invest
JT  - Cancer investigation
JID - 8307154
RN  - 0 (Tumor Suppressor Protein p53)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Child
MH  - Disease-Free Survival
MH  - Female
MH  - *Gene Expression Profiling
MH  - *Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Osteosarcoma/*genetics/pathology
MH  - Receptor, ErbB-2/*biosynthesis/*genetics
MH  - Tumor Suppressor Protein p53/*biosynthesis/*genetics
EDAT- 2004/04/09 05:00
MHDA- 2004/04/22 05:00
CRDT- 2004/04/09 05:00
PHST- 2004/04/09 05:00 [pubmed]
PHST- 2004/04/22 05:00 [medline]
PHST- 2004/04/09 05:00 [entrez]
AID - 10.1081/cnv-120027577 [doi]
PST - ppublish
SO  - Cancer Invest. 2004;22(1):16-24. doi: 10.1081/cnv-120027577.